Association of FK506 binding protein 5 (FKBP5) gene rs4713916 polymorphism with mood disorders: A meta-analysis

Acta Neuropsychiatrica

Volumn 23, Issue 1, 2011, Pages 12-19

  Feng, Xiao Liang ^a   Wang, Fang ^a   Zou, Yan Feng ^a   Li, Wen Fei ^b   Tian, Yang Hua ^a   Pan, Fa Ming ^a   Huang, Fen ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b People's Hospital of Hefei   (China)

Author keywords

FK506 binding protein 5; genetic polymorphisms; meta analysis; mood disorders

Indexed keywords

FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 5; UNCLASSIFIED DRUG;

ARTICLE; CAUCASIAN; COCHRANE LIBRARY; DNA POLYMORPHISM; ETHNIC DIFFERENCE; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MEDLINE; META ANALYSIS; MOOD DISORDER;

EID: 78651232846     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2010.00514.x     Document Type: Article

References (37)

1. Lee S, Jeong J, Kwak Y, Park SK., Depression research: where are we now? Mol Brain 2010; 3: 8.
2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE., Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602. (Pubitemid 40973434)
3. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER., The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405-418.
4. Sartorius N., The economic and social burden of depression. J Clin Psychiatry 2001; 62: 8-11.
5. Wittchen HU, Jacobi F., Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15: 357-376.
6. Fan M, Liu B, Jiang T, Jiang X, Zhao H, Zhang J., Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders. Psychiatr Genet 2010; 20: 1-7.
7. Beckman G, Beckman L, Cedergren B, Perris C, Strandman E., Serum protein and red cell enzyme polymorphisms in affective disorders. Hum Hered 1978; 28: 41-47. (Pubitemid 8224004)
8. Lopez-Leon S, Janssens AC, Gonzalez-Zuloeta Ladd AM, et al., Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry 2008; 13: 772-785.
9. Holsboer F., The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999; 33: 181-214.
10. Holsboer F., The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501.
11. Nair SC, Rimerman RA, Toran EJ, et al., Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor. Mol Cell Biol 1997; 17: 594-603.
12. Cheng R, Juo SH, Loth JE, et al., Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol Psychiatry 2006; 11: 252-260.
13. Binder EB., The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 2009; 34: S186-S195.
14. Binder EB, Salyakina D, Lichtner P, et al., Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004; 36: 1319-1325.
15. Binder EB, Bradley RG, Liu W, et al., Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008; 299: 1291-1305.
16. Zobel A, Schuhmacher A, Jessen F, et al., DNA sequence variants of the FKBP5 gene are associated with unipolar depression. Int J Neuropsychopharmacol 2010; 13: 649-660.
17. Lavebratt C, Aberg E, Sjoholm LK, Forsell Y., Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J Affect Disord 2010; 125: 249-255.
18. Lekman M, Laje G, Charney D, et al., The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry 2008; 63: 1103-1110.
19. Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R, Fananas L., Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 2007; 104: 83-90.
20. Gawlik M, Moller-Ehrlich K, Mende M, et al., Is FKBP5 a genetic marker of affective psychosis? A case control study and analysis of disease related traits. BMC Psychiatry 2006; 6: 52.
21. Munafo MR, Flint J., Meta-analysis of genetic association studies. Trends Genet 2004; 20: 439-444.
22. Cochran WG., The combination of estimates from different experiments. Biometrics 1954; 10: 101-129.
23. Higgins JP, Thompson SG., Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
24. Mantel N, Haenszel W., Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
25. Dersimonian R, Laird N., Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
26. Egger M, Davey SG, Schneider M, Minder C., Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-634.
27. Willour VL, Chen H, Toolan J, et al., Family-based association of FKBP5 in bipolar disorder. Mol Psychiatry 2009; 14: 261-268.
28. Sarginson JE, Lazzeroni LC, Ryan HS, Schatzberg AF, Murphy GJ., FKBP5 polymorphisms and antidepressant response in geriatric depression. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 554-560.
29. Horstmann S, Lucae S, Menke A, et al., Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010; 35: 727-740.
30. Kirchheiner J, Lorch R, Lebedeva E, et al., Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 2008; 9: 841-846.
31. Tsai SJ, Hong CJ, Chen TJ, Yu YW., Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1097-1098.
32. Brent D, Melhem N, Ferrell R, et al., Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 2010; 167: 190-197.
33. Binder EB, Lucae S, Salyakina D, et al., SNPs in FKBP5 determine a novel subtype of depression characterized by rapid response to antidepressant treatment. Eur Neuropsychopharmacol 2006; 16 (Suppl. 1): S75.
34. Grad I, Picard D., The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrinol 2007; 275: 2-12.
35. Pace TW, Miller AH., Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci 2009; 1179: 86-105.
36. Maes M, Galecki P, Chang YS, Berk M., A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2010. [Epub ahead of print]
37. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG., Replication validity of genetic association studies. Nat Genet 2001; 29: 306-309.